Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Roberto Mencarelli is active.

Publication


Featured researches published by Roberto Mencarelli.


Annals of Surgical Oncology | 2003

Ratio Between Metastatic and Examined Lymph Nodes Is an Independent Prognostic Factor After D2 Resection for Gastric Cancer: Analysis of a Large European Monoinstitutional Experience

Donato Nitti; Alberto Marchet; M. Olivieri; Alessandro Ambrosi; Roberto Mencarelli; Claudio Belluco; Mario Lise

Background: In view of the lack of consensus on the level and number of lymph nodes to be examined for accurate staging of patients with gastric cancer, our aim was to evaluate the prognostic significance of lymph node status in a large European monoinstitutional experience.Methods: A review was made of our prospective database from 1980 to 2000, when 314 of 445 patients operated for gastric adenocarcinoma underwent radical resection (R0) with D2 lymphadenectomy. Survival was determined by the Kaplan-Meier method and differences were assessed by the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model in forward stepwise regression.Results: In 277 evaluable patients, 5-year survival was 57% (median follow-up, 48 months; range, 2–251). A total of 7668 lymph nodes were examined (median, 27; range, 11–62). The 5-year survivals according to the metastatic/examined lymph nodes ratio (N ratio) were 14%, 50%, 61%, and 82% in the group of patients with N ratio >25%, 11%–25%, 1%–10%, and 0%, respectively (P < .0001). At multivariate analysis, the N ratio was the best single independent prognostic factor (P = .000).Conclusions: After R0 resection for gastric cancer, the N ratio is a potent prognostic factor. It should therefore be considered in the clinical decision making process.


International Journal of Cancer | 2003

Gastrointestinal stromal tumors: From a surgical to a molecular approach

Carlo Riccardo Rossi; Simone Mocellin; Roberto Mencarelli; Mirto Foletto; Pierluigi Pilati; Donato Nitti; Mario Lise

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. These tumors span a wide clinical spectrum from benign to malignant and have long been recognized for their nearly absolute resistance to chemotherapy and radiation treatment. We reviewed the worldwide experience on GIST diagnosis, prognosis and treatment and describe our own series. PubMed was searched for references using the terms gastrointestinal stromal tumor, GIST and gastrointestinal sarcoma. Recent reports were given emphasis because GIST is a novel clinical entity and older published work on gastrointestinal sarcomas might be contaminated with other histologic tumor types. At present, surgery is the standard treatment for primary resectable GIST. To increase the activity of conventional chemotherapeutic agents, locoregional therapies are being implemented in the clinical setting. A major breakthrough is the development of a new class of anticancer agents targeting tumor‐specific molecular abnormalities. Preliminary results on administration of imatinib mesylate, a signal transduction inhibitor, are particularly encouraging, showing potent activity of this drug against metastatic GIST. Molecular targeting of the critical pathogenetic mechanism underlying GIST might not only revolutionize the strategy to treat locally advanced and metastatic GIST but also improve disease control after macroscopically radical surgery.


BMC Cancer | 2005

Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast

G. Zavagno; Paolo Carcoforo; Renato Marconato; Zeno Franchini; Giuliano Scalco; Paolo Burelli; Paolo Pietrarota; Mario Lise; Roberto Mencarelli; Giovanni Capitanio; Andrea Ballarin; Maria Elena Pierobon; Giorgia Marconato; Donato Nitti

BackgroundSentinel lymph node (SLN) biopsy is an effective tool for axillary staging in patients with invasive breast cancer. This procedure has been recently proposed as part of the treatment for patients with ductal carcinoma in situ (DCIS), because cases of undetected invasive foci and nodal metastases occasionally occur. However, the indications for SLN biopsy in DCIS patients are controversial.The aim of the present study was therefore to assess the incidence of SLN metastases in a series of patients with a diagnosis of pure DCIS.MethodsA retrospective evaluation was made of a series of 102 patients who underwent SLN biopsy, and had a final histologic diagnosis of pure DCIS. Patients with microinvasion were excluded from the analysis. The patients were operated on in five Institutions between 1999 and 2004.Subdermal or subareolar injection of 30–50 MBq of 99 m-Tc colloidal albumin was used for SLN identification. All sentinel nodes were evaluated with serial sectioning, haematoxylin and eosin staining, and immunohistochemical analysis for cytocheratin.ResultsOnly one patient (0.98%) was SLN positive. The primary tumour was a small micropapillary intermediate-grade DCIS and the SLN harboured a micrometastasis. At pathologic revision of the specimen, no detectable focus of microinvasion was found.ConclusionOur findings indicate that SLN metastases in pure DCIS are a very rare occurrence. SLN biopsy should not therefore be routinely performed in patients who undergo resection for DCIS. SLN mapping can be performed, as a second operation, in cases in which an invasive component is identified in the specimen. Only DCIS patients who require a mastectomy should have SLN biopsy performed at the time of breast operation, since in these cases subsequent node mapping is not feasible.


Cancer | 2008

Role of resection margins in patients treated with breast conservation surgery.

G. Zavagno; Elena Goldin; Roberto Mencarelli; Giovanni Capitanio; Paola Del Bianco; Renato Marconato; Simone Mocellin; Giorgia Marconato; V. Belardinelli; Francesca Marcon; Donato Nitti

After breast conservation therapy (BCT), margin status is routinely evaluated to select patients who need reexcision. The aim of this study was to investigate how margin status and other clinicopathologic factors correlate with the presence of residual tumor at reexcision.


European Journal of Cancer Prevention | 2009

Gastrointestinal stromal tumors: Report of an audit and review of the literature

Guido Biasco; Daniela Velo; Imerio Angriman; M. Astorino; Anna Baldan; Matteo Baseggio; Umberto Basso; G. Battaglia; Matteo Bertin; Roberta Bertorelle; Paolo Bocus; Piero Brosolo; Andrea Bulzacchi; Renato Cannizzaro; Gian Franco Da Dalt; Monica Di Battista; Domenico Errante; Marny Fedrigo; Sergio Frustaci; Ivana Lionetti; Marco Massani; Roberto Mencarelli; Maria Cristina Montesco; Lorenzo Norberto; Maria Abbondanza Pantaleo; Claudio Pasquali; Davide Pastorelli; Carlo Rossi; Cesare Ruffolo; Luigi Salvagno

Gastrointestinal stromal tumors (GISTs), tumors characterized by c-KIT mutations, are the most frequent mesenchymal tumors of the digestive tract. The stomach is the most commonly involved site. Localization, size and mitotic rate are reliable predictors of survival and the two milestones of GISTs treatment are surgery and imatinib. This article is aimed to report the data of an audit, carried out on the morphological and clinical aspects of the disease and to review the present knowledge on GISTs. A total of 172 patients with GISTs (M : F=1 : 1; mean age 65 years) were recruited. The stomach was the most frequently involved site. In 50% of the cases the tumor was smaller than 5 cm, whereas major symptoms were observed in 43% of the cases. Predictors of progressive disease were present only in a small percentage of cases but the disease was in the metastatic phase in over 25% of the cases at diagnosis. Familial aggregation was rare but a consistent share of the patients (21%) had other synchronous or metachronous cancers. The most frequent mutations were in-frame deletions and point mutations of c-KIT exon 11. This report confirms in part the available data on GIST in a consecutive series of patients recruited in Italy and shows that only large collaborative multicenter studies provide data sound enough to enable making reasonable clinical and therapeutic choices, and suggests that, as a measure of secondary prevention, a diagnostic definition should be obtained in all submucosal lesions of the GI tract and that GIST patients should be screened for second tumors.


British Journal of Surgery | 2009

Prognostic value of subclassification of T2 tumours in patients with gastric cancer.

Donato Nitti; Alberto Marchet; Simone Mocellin; Gm Rossi; Alessandro Ambrosi; Roberto Mencarelli

This study was designed to evaluate the prognostic value of tumour stage T2 subcategorization (T2a and T2b) in patients with gastric carcinoma.


Surgery Today | 2005

True Solitary Pancreatic Cyst in an Adult: Report of a Case

Pietro Fiamingo; Massimiliano Veroux; Enrico Gringeri; Roberto Mencarelli; Pierfrancesco Veroux; Carmelo Madia; Davide D'Amico

The differential diagnosis of cystic neoformations in the pancreas is challenging. We report a case of a true solitary cyst of the pancreas in a 26-year old woman. Abdominal magnetic resonance imaging and computed tomography showed a unilocular neoformation in the head of the pancreas, without obstruction of Wirsungs duct. We excised the cyst and performed Roux-en-Y loop pancreaticojejunostomy, but the patient suffered recurrent acute pancreatitis from Wirsungs duct stenosis. Thus, a new Roux-en-Y loop pancreaticojejunostomy was successfully done 6 months later. Histologically, the cyst was lined by cuboidal epithelium, immunohistochemically positive to anti-carbohydrate antigen 19-9 antibodies. To our knowledge, only 11 cases of solitary true cyst of the pancreas in adults have been reported, so the characteristics of this unusual entity are not well known. We propose a scheme for the differential diagnosis of cystic neoformations of the pancreas, starting from the histopathological definition of a true solitary cyst.


Tumori | 2008

Correlation between magnetic resonance imaging and histopathological tumor response after neoadjuvant chemotherapy in breast cancer.

Maria Ornella Nicoletto; Donato Nitti; L. Pescarini; Francesco Corbetti; Roberto Mencarelli; Alessandro Cappetta; Alessandra Galligioni; Claudia Pogliani; Alberto Marchet; Fernando Bozza; Cristina Ghiotto; Luciano Griggio; G. Zavagno; Martin Donach; Cosimo di Maggio

AIM To evaluate the accuracy of magnetic resonance imaging in assessing tumor response following neoadjuvant chemotherapy in patients with locally advanced breast cancer. MATERIALS AND METHODS Twenty-six patients entered a phase II study of neoadjuvant chemotherapy, undergoing bilateral breast magnetic resonance imaging before therapy and before surgery. Tumor response was classified using RECIST criteria, using tumor size at magnetic resonance imaging. The latter was then compared to residue found at histopathological examination. RESULTS Magnetic resonance imaging showed 6 (23%) complete responses, 17 (65%) partial responses, 3 (11.5%) disease stabilizations and no disease progressions. Twenty-three tumors (88.5%) were considered responsive and 3 (11.5%) unresponsive. Pathological tumor response was: 6 complete responses (23%), 17 partial responses (65%), 2 stable disease (8%), 1 progression (4%). When results of the preoperative magnetic resonance imaging were compared to pathological tumor response, magnetic resonance imaging overestimated tumor size in 12 cases (46%) and underestimated it in 9 (35%). However, preoperative magnetic resonance imaging failed to detect invasive tumor in 2 false-negative cases (8%), 1 of which was multifocal. Mastectomy was performed in 12 cases: 1 case of disease progression even though the neoplasm appeared smaller at magnetic resonance imaging, 3 cases with stable disease, and 4 cases with T3 or T4 disease. The 9th patient was T2N2 with initial retroareolar disease and negative magnetic resonance imaging after chemotherapy. The 10th patient, affected by lobular cancer, was in partial remission but was T3N1. The 11th patient was 57 years old but was not interested in conservative surgery. The 12th patient requested bilateral prophylactic mastectomy due to her positive family history of breast cancer. CONCLUSIONS Magnetic resonance imaging of the breast allowed conservative surgery in 54% of the patients. This low value is primarily due to overestimation of tumor size, with a negative predictive value of 67% in our population. However, surgeons were able to choose conservative surgery with relative safety in cases of small residual disease.


Diagnostic Pathology | 2013

Telepathology in cervical and breast cancer screening programmes

Romano Colombari; Roberto Mencarelli; Alessio Gasparetto; Carla Cogo; Antonio Rizzo

In Veneto, Italy, an organized effective mass-screening programme for cervical and breast cancer has been active. An Aperio ScanScope-XT slide scanner have been applied to EQA since 2009.


Clinical Nuclear Medicine | 2013

Intraoperative hand-held imaging γ-camera for sentinel node detection in patients with breast cancer: feasibility evaluation and preliminary experience on 16 patients.

Sotirios Chondrogiannis; Alice Ferretti; Enzo Facci; Maria Cristina Marzola; Lucia Rampin; Sara Tadayyon; Margherita Maffione; Domenico Reale; Roberto Mencarelli; Domenico Rubello

Purpose This study aimed to assess the feasibility and potential usefulness of a new intraoperative portable high-resolution imaging &ggr;-camera for the localization of sentinel lymph node in patients with breast cancer. Methods Sixteen T1 to T2 breast cancer female patients were evaluated (mean age, 62 years) with preoperative lymphoscintigraphy, acquired 30 minutes after intradermal injection of 60 to 70 MBq (1.6-1.9 mCi) of 99mTc-nanocolloids in saline volumes of 0.1 to 0.2 mL. Surgery took place the day after (18-20 hours after tracer injection). For intraoperative sentinel lymph node localization, a traditional &ggr;-probe was used by the surgeon. Moreover, a portable imaging &ggr;-camera was used by the nuclear physician who was present in the operating room. Results The portable imaging &ggr;-camera showed very high spatial resolution (2.4 mm) in the 4.4 × 4.4 cm2 FOV, with a good sensitivity of 180 cps/MBq at a Plexiglas depth of 1 cm. In 11 patients, lymphoscintigraphy, &ggr;-probe, and imaging &ggr;-camera depicted the same number of radioactive lymph nodes (17 nodes; 5 of which were metastatic and detected in 6 different patients). In 6 patients, the portable imaging &ggr;-camera detected 1 node more than lymphoscintigraphy (in total, 5 nodes more), one of which was metastatic (the only one metastatic in that patient). Conclusions Our preliminary results showed that a portable high-resolution hand-held imaging &ggr;-camera is a feasible, not time-consuming, noninvasive procedure in intraoperative sentinel node localization, offering extra confidence to the surgeon. In our hands, it was a very useful auxiliary imaging tool especially in the identification of nodes located deep in the axilla, which are difficult to detect at the preoperative lymphoscintigraphy. Additional multicenter studies involving a greater number of patients are necessary to confirm these promising data.

Collaboration


Dive into the Roberto Mencarelli's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge